
The Precision Cancer Consortium (PCC) is a non-profit organization comprised of seven pharmaceutical companies focused on driving global access to comprehensive genomic profiling (CGP) for cancer patients. Their mission is to make precision oncology and CGP the standard of care. The PCC facilitates collaboration among its members to address challenges related to access, awareness, and the research and development of CGP. They have strategic objectives to increase patient access to CGP, educate stakeholders on its benefits, and overcome implementation challenges in healthcare systems. PCC collaborates with other organizations on specific projects, such as developing a genomic testing cost calculator with IQVIA and AI-driven trial matching with Massive Bio.

The Precision Cancer Consortium (PCC) is a non-profit organization comprised of seven pharmaceutical companies focused on driving global access to comprehensive genomic profiling (CGP) for cancer patients. Their mission is to make precision oncology and CGP the standard of care. The PCC facilitates collaboration among its members to address challenges related to access, awareness, and the research and development of CGP. They have strategic objectives to increase patient access to CGP, educate stakeholders on its benefits, and overcome implementation challenges in healthcare systems. PCC collaborates with other organizations on specific projects, such as developing a genomic testing cost calculator with IQVIA and AI-driven trial matching with Massive Bio.